Association of RAGE polymorphisms and cancer risk: a meta-analysis of 27 studies

详细信息    查看全文

• 作者：Wenjie Xia ; Youtao Xu ; Qixing Mao ; Gaochao Dong ; Run Shi ; Jie Wang…
• 关键词：RAGE ; Polymorphism ; 82G/S ; ?74T/A ; ?29T/C ; Cancer risk
• 刊名：Medical Oncology
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：32
• 期：2
• 全文大小：600 KB
• 参考文献：1. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267(21):14998-004.
  2. Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab. 2008;4(5):285-3. doi:10.1038/ncpendmet0786 . CrossRef
  3. Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, Schmidt AM. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med. 2007;7(8):743-1. CrossRef
  4. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003;198(10):1507-5. doi:10.1084/jem.20030800 . CrossRef
  5. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Investig. 2001;108(7):949-5. doi:10.1172/JCI14002 . CrossRef
  6. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2005;83(11):876-6. doi:10.1007/s00109-005-0688-7 . CrossRef
  7. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D, et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl med. 2009;7:38. doi:10.1186/1479-5876-7-38 . CrossRef
  8. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007;13(10):2836-8. doi:10.1158/1078-0432.CCR-06-1953 . CrossRef
  9. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate. 2005;64(1):92-00. doi:10.1002/pros.20219 . CrossRef
  10. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol. 2002;196(2):163-0. doi:10.1002/path.1031 . CrossRef
  11. Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol. 2010;136(5):677-4. doi:10.1007/s00432-009-0706-1 . CrossRef
  12. Shastry BS. SNPs: impact on gene function and phenotype. Methods Mol Biol. 2009;578:3-2. doi:10.1007/978-1-60327-411-1_1 . CrossRef
  13. Dabritz J, Friedrichs F, Weinhage T, Hampe J, Kucharzik T, Lugering A, et al. The functional ?74T/A polymorphism of the receptor for advanced glycation end products may modulate Crohn’s disease. Am J Physiol Gastrointest Liver Physiol. 2011;300(5):G823-2. doi:10.1152/ajpgi.00115.2010 . CrossRef
  
• 刊物主题：Oncology; Hematology; Pathology; Internal Medicine;
• 出版者：Springer US
• ISSN：1559-131X

文摘

The receptor for advanced glycation end products (RAGE), a member of immunoglobulin superfamily, has been proved to stimulate survival, growth, and metastatic spread of cancers cells. Evidence suggested that the 82G/S, ?74T/A, and ?29T/C polymorphisms in RAGE promoter region might affect the risk of cancer; however, data from epidemiological studies showed conflicting results that remain to be further clarified. This meta-analysis was performed to derive a more precise estimation of 82G/S, ?74T/A, and ?29T/C polymorphisms and risk of cancer. A comprehensive electronic search was conducted for articles published up until December 2, 2014, in Medline (PubMed), Embase, the Cochrane Library and Google Scholar. A total of 12 case–control articles were included in this meta-analysis, providing 3,374 cases and 3,757 controls for 82G/S, 2,936 cases and 3,338 controls for ?74T/A, and 2,882 cases and 3,279 controls for ?29T/C specifically. The pooled odds ratio (OR) with 95?% confidence interval (CI) was calculated to evaluate the associations with risk of cancer. Overall, we observed significantly increased risk of cancer in relation to 82G/S (A vs. G: OR 1.321, 95?% CI 1.164-.499, P het 0.028; AA vs. GG: OR 1.823, 95?% CI 1.541-.157, P het?P het 0.002; GA+AA vs. GG: OR 1.470, 95?% CI 1.187-.821, P het 0.002; AA vs. GG+AG: OR 1.416, 95?% CI 1.158-.732, P het 0.107) and reduced risk of cancer in relation to ?74T/A (AA vs. TT: OR 0.818, 95?% CI 0.686-.976, P het 0.025; A vs. T: OR 0.908, 95?% CI 0.840-.981, P het 0.014). In subgroup analysis for 82G/S, a significantly elevated cancer risk was indicated in the population of Asian and patients with lung cancer, and for ?74T/A, reduced risk was indicated in population of Caucasian and patients with lung cancer and breast cancer. But no significant association was observed between ?29T/C and risk of cancer. Thus, this meta-analysis revealed that 82G/S polymorphism is associated with a significantly increased risk of cancer, while ?74T/A polymorphism is associated with a reduced risk of cancers.